BTG1 Activators are a specialized class of chemical compounds that facilitate the increased functional activity of BTG1, a protein that plays a pivotal role in cellular processes like cell growth, differentiation, and gene regulation. This category of chemical activators operates through various cellular pathways, ensuring that the activity of BTG1 is enhanced without altering its expression levels. For instance, some activators may interact with the transcription machinery, leading to the post-translational modifications of BTG1 that promote its activity. Others might engage with signaling pathways that converge on the cellular locales where BTG1 exerts its functions, subsequently amplifying the protein's ability to modulate its target gene expressions. The precise mechanisms of each activator are deeply rooted in cellular biochemistry, focusing on the direct or indirect upregulation of BTG1's activity through conformational changes or interaction with partner molecules that stabilize BTG1 in its active form.
Furthermore, BTG1 Activators may influence the degradation pathways of the protein, such as the ubiquitin-proteasome system, thereby prolonging the half-life of BTG1 and allowing it to remain active within the cell for an extended period. Some activators may even affect the localization of BTG1, causing it to accumulate in specific sub-cellular compartments where it is most effective in exerting its regulatory functions. By modulating the cellular environment and the complex network of interactions in which BTG1 is involved, these activators ensure that the protein can adequately perform its role in controlling cell cycle progression and apoptosis. Through these intricate and targeted mechanisms, BTG1 Activators are essential in maintaining the delicate balance of cellular proliferation and differentiation, highlighting their significant role in the nuanced regulation of BTG1-dependent pathways.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises intracellular cAMP levels, which in turn can activate PKA. PKA phosphorylation events may enhance the activity of BTG1 by promoting cellular processes such as anti-proliferative signaling, where BTG1 is known to be involved. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
As a cAMP analog, Dibutyryl-cAMP activates PKA, potentially elevating the anti-proliferative and differentiation effects where BTG1 has a functional role. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator, and PKC activation can lead to signaling cascades that may enhance BTG1's involvement in cell cycle regulation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor that might reduce competitive signaling pathways, thereby potentially enhancing BTG1's roles in DNA repair and cell cycle control. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which may result in the activation of stress-related pathways where BTG1 could be more actively involved in regulating cellular responses to DNA damage. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which could lead to the enhancement of BTG1's role in growth arrest and cell cycle control as the cell responds to reduced protein synthesis signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As a MEK inhibitor, PD98059 may shift signaling pathways to favor those that enhance BTG1 activity, particularly in aspects of cell cycle arrest and differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound inhibits p38 MAPK, potentially enhancing the stress response pathways that BTG1 may regulate. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 could potentiate BTG1's role in apoptosis and cellular stress responses by altering JNK pathway activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
As a PI3K inhibitor, Wortmannin might enhance BTG1's involvement in the regulation of cell growth and apoptosis through altered signaling. |